{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:54:57Z","timestamp":1790826897393,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.14310\/horm.2002.1438","type":"journal-article","created":{"date-parts":[[2014,2,10]],"date-time":"2014-02-10T12:33:18Z","timestamp":1392035598000},"page":"507-516","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A review of the metabolic effects of controlled-release Phentermine\/Topiramate"],"prefix":"10.1007","volume":"12","author":[{"given":"Dimitrios N.","family":"Kiortsis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,15]]},"reference":[{"key":"12040507_CR1","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1001\/jama.288.14.1723","volume":"288","author":"KM Flegal","year":"2002","unstructured":"Flegal KM, Carroll MD, Ogden CK, Johnson CL, 2002 Prevalence and trends in obesity among US adults, 1999\u20132000. J Am Med Assoc 288: 1723\u20131727.","journal-title":"J Am Med Assoc"},{"key":"12040507_CR2","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1161\/01.CIR.0000145546.97738.1E","volume":"110","author":"S Klein","year":"2004","unstructured":"Klein S, Burke LE, Bray GA, et al, 2004 Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 110: 2952\u20132967.","journal-title":"Circulation"},{"key":"12040507_CR3","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1161\/CIRCULATIONAHA.106.171016","volume":"113","author":"P Poirier","year":"2006","unstructured":"Poirier P, Giles TD, Bray GA, et al, 2006 Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 113: 898\u2013918.","journal-title":"Circulation"},{"key":"12040507_CR4","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1365-2125.2009.03549.x","volume":"68","author":"DJ Heal","year":"2009","unstructured":"Heal DJ, Gosden J, Smith SL, 2009 Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br J Clin Pharmacol 68: 861\u2013874.","journal-title":"Br J Clin Pharmacol"},{"key":"12040507_CR5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1301\/nr.2004.jul.S120-S126","volume":"62","author":"FX Pi-Sunyer","year":"2004","unstructured":"Pi-Sunyer FX, 2004 The epidemiology of central fat distribution in relation to disease. Nutr Rev 62: 120\u2013126.","journal-title":"Nutr Rev"},{"key":"12040507_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S1262-3636(07)70161-1","volume":"31","author":"DN Kiortsis","year":"2005","unstructured":"Kiortsis DN, Filippatos TD, Elisaf MS, 2005 The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabet Metab 31: 15\u201322.","journal-title":"Diabet Metab"},{"key":"12040507_CR7","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1185\/030079905X38132","volume":"21","author":"TD Filippatos","year":"2005","unstructured":"Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS, 2005 A review of the metabolic effects of sibutramine. Curr Med Res Op 21: 457\u2013466.","journal-title":"Curr Med Res Op"},{"key":"12040507_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1365-2710.2010.01164.x","volume":"36","author":"FD Christopoulou","year":"2011","unstructured":"Christopoulou FD, Kiortsis DN, 2011 An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. J Clin Pharm Ther 36: 10\u201318.","journal-title":"J Clin Pharm Ther"},{"key":"12040507_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4093\/dmj.2012.36.1.13","volume":"36","author":"JG Kang","year":"2012","unstructured":"Kang JG, Park CY, 2012 Anti-Obesity Drugs: A Review about Their Effects and Safety. Diabetes Metab J 36: 13\u201325.","journal-title":"Diabetes Metab J"},{"key":"12040507_CR10","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1177\/193229680800200525","volume":"2","author":"DC Klonoff","year":"2008","unstructured":"Klonoff DC, Greenway F, 2008 Drugs in the pipeline for the obesity market. J Diabetes Sci Technol 2: 913\u2013918.","journal-title":"J Diabetes Sci Technol"},{"key":"12040507_CR11","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1586\/erc.10.125","volume":"8","author":"H Bays","year":"2010","unstructured":"Bays H, 2010 Phentermine, topiramate and their combination for the treatment of adiposopathy (\u2018sick fat\u2019) and metabolic disease. Expert Rev Cardiovasc Ther 8: 1777\u20131801.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"12040507_CR12","doi-asserted-by":"publisher","first-page":"532","DOI":"10.7326\/0003-4819-142-7-200504050-00012","volume":"142","author":"Z Li","year":"2005","unstructured":"Li Z, Maglione M, Tu W, et al, 2005 Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 142:532\u2013546.","journal-title":"Ann Intern Med"},{"key":"12040507_CR13","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1001\/archinte.161.15.1814","volume":"161","author":"G Glazer","year":"2001","unstructured":"Glazer G, 2001 Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch Intern Med 161: 1814\u20131824.","journal-title":"Arch Intern Med"},{"key":"12040507_CR14","doi-asserted-by":"publisher","first-page":"179674","DOI":"10.1155\/2011\/179674","volume":"2011","author":"LL Ioannides-Demos","year":"2011","unstructured":"Ioannides-Demos LL, Piccenna L, McNeil JJ, 2011 Pharmacotherapies for obesity: past, current, and future therapies. J Obes 2011: 179674.","journal-title":"J Obes"},{"key":"12040507_CR15","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1007\/s11095-010-0341-1","volume":"28","author":"RF Witkamp","year":"2011","unstructured":"Witkamp RF, 2011 Current and future drug targets in weight management. Pharm Res 28: 1792\u20131818.","journal-title":"Pharm Res"},{"key":"12040507_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/sj.ijo.0801889","volume":"26","author":"CK Haddock","year":"2002","unstructured":"Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M, 2002 Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 26: 262\u2013273.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"12040507_CR17","first-page":"1","volume":"103","author":"PG Shekelle","year":"2004","unstructured":"Shekelle PG, Morton SC, Maglione M, et al, 2004 Pharmacological and surgical treatment of obesity. Evid Rep Technol Assess 103: 1\u20136.","journal-title":"Evid Rep Technol Assess"},{"key":"12040507_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.pbb.2010.07.020","volume":"97","author":"GA Kennett","year":"2010","unstructured":"Kennett GA, Clifton PG, 2010 New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier? Pharmacol Biochem Behav 97: 63\u201383.","journal-title":"Pharmacol Biochem Behav"},{"key":"12040507_CR19","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00228-007-0318-0","volume":"63","author":"Y Khazaal","year":"2007","unstructured":"Khazaal Y, Zullino DF, 2007 Topiramate-induced weight loss is possibly due to the blockade of conditioned and automatic processes. Eur J Clin Pharmacol, 63: 891\u2013892.","journal-title":"Eur J Clin Pharmacol"},{"key":"12040507_CR20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1176\/appi.ajp.160.2.255","volume":"160","author":"SL McElroy","year":"2003","unstructured":"McElroy SL, Arnold LM, Shapira NA, et al, 2003 Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlledtrial. Am J Psychiatry 160: 255\u2013261.","journal-title":"Am J Psychiatry"},{"key":"12040507_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1471-244X-6-22","volume":"6","author":"Y Khazaal","year":"2006","unstructured":"Khazaal Y, Zullino DF, 2006 Topiramate in the treatment of compulsive sexual behavior: case report. BMC Psychiatry 6: 22.","journal-title":"BMC Psychiatry"},{"key":"12040507_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.brainres.2009.01.016","volume":"1262","author":"CI Turenius","year":"2009","unstructured":"Turenius CI, Htut MM, Prodon DA, et al, 2009 GABA(A) receptors in the lateral hypothalamus as mediators of satiety and body weight regulation. Brain Res 1262: 16\u201324.","journal-title":"Brain Res"},{"key":"12040507_CR23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.cmet.2006.08.002","volume":"4","author":"N Erondu","year":"2006","unstructured":"Erondu N, Gantz I, Musser B, et al, 2006 Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 4: 275\u2013282.","journal-title":"Cell Metab"},{"key":"12040507_CR24","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1038\/sj.npp.1300178","volume":"28","author":"H Husum","year":"2003","unstructured":"Husum H, Van Kammen D, Termeer E, Bolwig G, Math\u00e9 A, 2003 Topiramate normalizes hippocampal NPY-LI in flinders sensitive line \u2018depressed\u2019 rats and upregulates NPY, galanin, and CRH-LI in the hypothalamus: implications for mood-stabilizing and weight loss-inducing effects. Neuropsychopharmacology 28: 1292\u20131299.","journal-title":"Neuropsychopharmacology"},{"key":"12040507_CR25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1055\/s-0030-1248289","volume":"118","author":"M Sch\u00fctt","year":"2010","unstructured":"Sch\u00fctt M, Brinkhoff J, Drenckhan M, Lehnert H, Sommer C, 2010 Weight reducing and metabolic effects of topiramate in patients with migraine\u2014an observational study. Exp Clin Endocrinol Diabetes 118: 449\u2013452.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"12040507_CR26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/WNF.0b013e318157c5ce","volume":"31","author":"FM Theisen","year":"2008","unstructured":"Theisen FM, Beyenburg S, Gebhardt S, et al, 2008 A prospective study of body weight and serum leptin levels in patients treated with topiramate. Clin Neuropharmacol 31: 226\u2013230.","journal-title":"Clin Neuropharmacol"},{"key":"12040507_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00228-006-0220-1","volume":"63","author":"A Tremblay","year":"2007","unstructured":"Tremblay A, Chaput JP, B\u00e9rub\u00e9-Parent S, et al, 2007 The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension. Eur J Clin Pharmacol 63: 123\u2013134.","journal-title":"Eur J Clin Pharmacol"},{"key":"12040507_CR28","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/med.20021","volume":"25","author":"JY Winum","year":"2005","unstructured":"Winum JY, Scozzafava A, Montero JL, Supuran CT, 2005 Sulfamates and their therapeutic potential. Med Res Rev 25: 186\u2013228.","journal-title":"Med Res Rev"},{"key":"12040507_CR29","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.1016\/j.bmcl.2008.07.010","volume":"18","author":"SA Poulsen","year":"2008","unstructured":"Poulsen SA, Wilkinson BL, Innocenti A, Vullo D, Supuran CT, 2008 Inhibition of human mitochondrial carbonic anhydrases VA and VB with para-(4-phenyltriazole-1-yl)-benzenesulfonamide derivatives. Bioorg Med Chem Lett 18: 4624\u20134627.","journal-title":"Bioorg Med Chem Lett"},{"key":"12040507_CR30","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1021\/jm031057+","volume":"47","author":"D Vullo","year":"2004","unstructured":"Vullo D, Franchi M, Gallori E, Antel J, Scozzafava A, Supuran CT, 2004 Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclicsulfonamides. J Med Chem 47: 1272\u20131279.","journal-title":"J Med Chem"},{"key":"12040507_CR31","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S0899-9007(00)00452-4","volume":"16","author":"D Richard","year":"2000","unstructured":"Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y, 2000 Influence of topiramate in the regulation of energy balance. Nutrition 16: 961\u2013966.","journal-title":"Nutrition"},{"key":"12040507_CR32","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","volume":"377","author":"KM Gadde","year":"2011","unstructured":"Gadde KM, Allison DB, Ryan DH, et al, 2011 Effects of low dose, controlled release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 377: 1341\u20131352.","journal-title":"Lancet"},{"key":"12040507_CR33","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3945\/ajcn.111.024927","volume":"95","author":"WT Garvey","year":"2012","unstructured":"Garvey WT, Ryan DH, Look M, et al, 2012 Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 95: 297\u2013308.","journal-title":"Am J Clin Nutr"},{"key":"12040507_CR34","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/oby.2011.330","volume":"20","author":"DB Allison","year":"2012","unstructured":"Allison DB, Gadde KM, Garvey WT, et al, 2012 Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 20: 330\u2013342.","journal-title":"Obesity (Silver Spring)"},{"key":"12040507_CR35","doi-asserted-by":"crossref","unstructured":"Garvey WT, Ryan DH, Henry R, et al, 2013 Prevention of type 2 Diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care [epub ahead of print]","DOI":"10.2337\/dc13-1518"},{"key":"12040507_CR36","doi-asserted-by":"publisher","first-page":"405e1","DOI":"10.1016\/j.ajog.2012.07.008","volume":"207","author":"AV Margulis","year":"2012","unstructured":"Margulis AV, Mitchell AA, Gilboa SM, et al, 2012 Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol 207: 405e1\u20137.","journal-title":"Am J Obstet Gynecol"},{"key":"12040507_CR37","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1111\/j.1526-4610.2012.02190.x","volume":"52","author":"MW Green","year":"2012","unstructured":"Green MW, Seeger JD, Peterson C, Bhattacharyya A, 2012 Utilization of topiramate during pregnancy and risk of birth defects. Headache 52: 1070\u20131084.","journal-title":"Headache"},{"key":"12040507_CR38","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1212\/01.wnl.0000318293.28278.33","volume":"71","author":"S Hunt","year":"2008","unstructured":"Hunt S, Russell A, Smithson WH, et al, 2008 Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 71: 272\u2013276.","journal-title":"Neurology"},{"key":"12040507_CR39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(11)61080-5","volume":"378","author":"RB Malgarini","year":"2011","unstructured":"Malgarini RB, Pimpinella G, 2011 Phentermine plus topiramate in the treatment of obesity. Lancet 378: 125\u2013126.","journal-title":"Lancet"},{"key":"12040507_CR40","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.neuropharm.2012.01.017","volume":"63","author":"DJ Heal","year":"2012","unstructured":"Heal DJ, Gosden J, Smith SL, 2012 What is the prognosis for new centrally-acting anti-obesity drugs? Neuropharmacology 63: 132\u2013146.","journal-title":"Neuropharmacology"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.14310\/horm.2002.1438.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.14310\/horm.2002.1438\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.14310\/horm.2002.1438.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T15:37:23Z","timestamp":1739115443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.14310\/horm.2002.1438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["12040507"],"URL":"https:\/\/doi.org\/10.14310\/horm.2002.1438","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"25 September 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}